(Sharecast News) - Abivax shares surged on Tuesday after the French biotech released additional late-stage trial data that eased investor concerns over the safety of its lead ulcerative colitis treatment, obefazimod, while also highlighting further efficacy in difficult-to-treat patients.
The stock jumped more than 30% after the company said malignancies observed...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE